Clemence Mediavilla

Pessac-sur-dordogne, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

The Reply.

The Reply.

Journal: The American journal of medicine
Published: May 21, 2026

Autoimmunity and peginterferon therapy for polycythemia vera.

Autoimmunity and peginterferon therapy for polycythemia vera.

Journal: HemaSphere
Published: March 27, 2026

Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)

Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)

Journal: Bulletin du cancer
Published: January 28, 2026

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Journal: Leukemia
Published: August 20, 2025

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.

Journal: Leukemia
Published: August 20, 2025

TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costs.

TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costs.

Journal: The American journal of medicine
Published: June 25, 2025

A molecular signature predicts hematologic evolution in polycythemia vera patients.

A molecular signature predicts hematologic evolution in polycythemia vera patients.

Journal: Leukemia
Published: April 03, 2025

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology
Published: March 24, 2025

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.

Journal: HemaSphere
Published: March 17, 2025

Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitor.

Relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia responds well to a combination of modified hyper-CVAD, blinatumomab and tyrosine kinase inhibitor.

Journal: EJHaem
Published: August 03, 2024

Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)

Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)

Journal: Bulletin du cancer
Published: April 18, 2024

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Haematology
Published: March 15, 2024
Showing 1-12 of 32

Last Updated: 09/26/2026